Physician profile
Francois Andre Bethoux
NPI 1790727469
$39,371.97
in general payments reported to CMS, 2019-2025
11 companies · $7,150 in 2025
The $7,150 reported for 2025 was more than what 97% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,785 · 2021: $5,990 · 2022: $2,635 · 2023: $13.37 · 2024: $7,003 · 2025: $7,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,040.00 |
| Food and Beverage | $126.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $15,931.34 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $14,040.00 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $3,694.93 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $2,600.00 | 2022 | |
| Genentech, INC. | $1,695.00 | 2020 | |
| Gw Pharma Limited | $1,250.00 | 2020 | |
| Celgene Corporation | $99.47 | 2024 | Zeposia |
| Penumbra, INC. | $34.69 | 2022 | |
| Tg Therapeutics, INC. | $26.54 | 2023-2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francois Bethoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.